Medicare Advantage and Prescription Drug Program: Final Marketing Provisions CFR 422.111(a)(3) and 423.128(a)(3) (CMS-10260)

ICR 201804-0938-018

OMB: 0938-1051

Federal Form Document

Forms and Documents
Document
Name
Status
Supporting Statement A
2018-11-21
IC Document Collections
ICR Details
0938-1051 201804-0938-018
Active 201712-0938-001
HHS/CMS CM-CPC
Medicare Advantage and Prescription Drug Program: Final Marketing Provisions CFR 422.111(a)(3) and 423.128(a)(3) (CMS-10260)
Revision of a currently approved collection   No
Regular
Approved with change 12/03/2018
Retrieve Notice of Action (NOA) 05/11/2018
Previous terms continue: Approval of this package is based on the understanding that the program staff will update appropriate OMB staff annually on any changes within the package. At the time of the briefing, OMB staff will determine if such changes are non-substantive or substantive.
  Inventory as of this Action Requested Previously Approved
12/31/2021 36 Months From Approved 05/31/2020
41,091 0 805
29,803 0 9,660
8,068,730,000 0 0

This final rule implements provisions of the Social Security Act (the Act) establishing and regulating the Medicare Advantage (MA) program. The MA program was enacted in Title II of The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) on December 8, 2003. The MA program replaces the Medicare+Choice (M+C) program established under Part C of the title XVIII of the Act, while retaining most key features of the M+C program. The MA program attempts to broadly reform and expand the availability of private health plan options to Medicare beneficiaries. Medicare Advantage (MA) organizations and Prescription Drug Plan Sponsors use the information to comply with the eligibility requirements and the MA and Part D contract requirements. CMS will use this information to ensure that correct information is disclosed to Medicare beneficiaries, both potential enrollees and enrollees.

PL: Pub.L. 108 - 117 201 Name of Law: The Medicare Prescription Drug, Improvement, and Modernization Act of 2003
   PL: Pub.L. 110 - 275 103 Name of Law: The Medicare Improvements for Patients and Providers Act of 2008
  
None

0938-AT08 Final or interim final rulemaking 83 FR 16440 04/16/2018

  82 FR 56336 11/28/2017
83 FR 16440 04/16/2018
No

2
IC Title Form No. Form Name
Marketing Materials
Annual Notice of Change (ANOC) and Evidence of Coverage (EOC)

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 41,091 805 0 40,286 0 0
Annual Time Burden (Hours) 29,803 9,660 0 20,143 0 0
Annual Cost Burden (Dollars) 8,068,730,000 0 0 0 8,068,730,000 0
Yes
Miscellaneous Actions
No
In line with CMS-4182-F (April 16, 2018; 83 FR 16440) we propose the following: ANOC/EOC Requirements (Time): No Change. ANOC/EOC Requirements (Costs): Now includes non-labor costs (paper, toner, and postage) of 8,068,730,000. ANOC/EOC Requirements (Documents): We propose to separate the .ANOC and EOC documents. Currently, they are approved as combined documents. Marketing Materials: Adds 20,143 hr burden.

$324,151
No
    No
    No
No
No
No
Uncollected
Mitch Bryman 410 786-5258 Mitch.Bryman@cms.hhs.gov

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
05/11/2018


© 2024 OMB.report | Privacy Policy